Effects of captopril and angiotensin II receptor blockers (AT 1, AT 2) on myocardial ischemia-reperfusion induced infarct size

Cytokine

Volumn 56, Issue 3, 2011, Pages 688-694

  Parlakpinar, Hakan ^a   Ozer, Mehmet Kaya ^b   Acet, Ahmet ^a  

^a INONU UNIVERSITY   (Turkey)

^b SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

AT 2 receptor; Captopril; Losartan; Myocardial ischemia reperfusion; PD123319

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CAPTOPRIL; LOSARTAN; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTROCARDIOGRAM; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART RATE; IN VIVO STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTERIES; BLOOD PRESSURE; CAPTOPRIL; HEART RATE; IMIDAZOLES; LOSARTAN; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NECROSIS; PYRIDINES; RATS; RATS, WISTAR; RISK FACTORS;

RATTUS;

EID: 81455131541     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.09.002     Document Type: Article

References (45)

1. Sahna E., Parlakpinar H., Turkoz Y., Acet A. Protective effects of melatonin on myocardial ischemia-reperfusion induced infarct size and oxidative changes. Physiol Res 2005, 54:491-495.
2. Ozdemir R., Parlakpinar H., Polat A., Colak C., Ermis N., Acet A. Selective endothelin a (ET(A)) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology 2006, 219:142-149.
3. Carden D.L., Granger D.N. Pathophysiology of ischaemia±reperfusion injury. J Pathol 2000, 190:255-266.
4. Carey R.M., Shetal H., Padia S.H. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 2008, 19:84-87.
5. Lenkei Z., Palkovits M., Corvol P., Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol 1997, 18:383-439.
6. Murugaiah A.M., Wallinder C., Mahalingam A.K., Wu X., Wan Y., Plouffe B., et al. Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system. Bioorg Med Chem 2007, 15:7166-7183.
7. Weidenbach R., Schulz R., Gres P., Behrends M., Post H., Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism. Br J Pharmacol 2000, 131:138-144.
8. Voros S., Yang Z., Bove C.M., Gilson W.D., Epstein F.H., French B.A., et al. Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling. Am J Physiol Heart Circ Physiol 2006, 290:H1004-H1010.
9. Zhun Z.Y., Sung L.H. Angiotensin-converting enzyme inhibition after myocardial infarction. Asian Cardiovasc Thorac Ann 2000, 8:85-90.
10. Liu Y.H., Yang X.P., Sharov V.G., Sigmon D.H., Sabbath H.N., Carretero O.A. Paracrine system in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996, 27:7-13.
11. Ozer M.K., Parlakpinar H., Acet A. Reduction of ischemia-reperfusion induced myocardial infarct size in rats by caffeic acid phenethyl ester (CAPE). Clin Biochem 2004, 37:702-705.
12. Parlakpinar H., Olmez E., Acet A., Ozturk F., Tasdemir S., Ates B., et al. Beneficial effects of apricot-feeding on myocardial ischemia-reperfusion injury in rats. Food Chem Toxicol 2009, 49:802-808.
13. Parlakpinar H., Sahna E., Acet A., Mizrak B., Polat A. Effect of caffeic acid phenethyl ester (CAPE) on myocardial ischemia-reperfusion induced apoptotic cell death. Toxicology 2005, 207:169-177.
14. Parlakpinar H., Ozer M.K., Acet A. Effect of aminoguanidine on ischemia-reperfusion induced myocardial injury in rats. Mol Cell Biochem 2005, 277:137-142.
15. Vakeva A.P., Agah A., Rollins S.A., Matis L.A., Li L., Stahl G.L. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998, 97:2259-2267.
16. Ertl G., Kloner R.A., Alexender R.W., Brauwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982, 65:40-48.
17. Noda K., Sasaguri M., Ideishi M., Ikeda M., Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 1993, 27:334-340.
18. Zhang C., Hein T.W., Wang W., Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003, 92:322-329.
19. Zhu Y.C., Zhu Y.Z., Lu N., Wang M.J., Wang Y.X., Yao T. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling. Clin Exp Pharmacol Physiol 2003, 30:911-918.
20. Cohn J.N., Goldman J.M. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. Am J Hypertens 2008, 21:248-256.
21. Lévy B.I. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004, 109:8-13.
22. Jalowy A., Schulz R., Dorge H., Behrends M., Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998, 32:1787-1796.
23. Campbell D.J., Krum H., Esler M.D. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005, 111:315-320.
24. Jugdutt B.I., Menon V. AT2 receptor and apoptosis during AT1 receptor blockade in reperfused myocardial infarction in the rat. Mol Cell Biochem 2004, 262:203-214.
25. Johren O., Dendorfer A., Dominiak P. Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res 2004, 62:460-467.
26. Adachi Y., Saito Y., Kishimoto I., Harada M., Kuwahara K., Takahashi N., et al. Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 2003, 107:2406-2408.
27. Xu J., Carretero O.A., Liu Y.H., Shesely E.G., Yang F., Kapke A., et al. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension 2002, 40:244-250.
28. Oishi Y., Ozono R., Yoshizumi M., Akishita M., Horiuchi M., Oshima T. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life Sci 2006, 80:82-88.
29. Liu Y.H., Yang X.P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure, role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997, 99:1926-1935.
30. Jugdutt B.I., Menon V. AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction. Mol Cell Biochem 2004, 260:111-118.
31. Xu Y., Menon V., Jugdutt B.I. Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-ε in acutely reperfused myocardial infarction. Effect of UP269-6 and losartan on AT1 and AT2 receptor expression, and IP3 receptor and PKCε proteins. J Renin Angiotensin Aldosterone Syst 2000, 1:184-195.
32. Jugdutt B.I., Balghith M. Enhanced regional AT2 receptor and PKCε expression during cardioprotection induced by AT1 receptor blockade after reperfused myocardial infarction. J Renin Angiotensin Aldosterone Syst 2001, 2:134-140.
33. Ford W.R., Clanachan A.S., Jugdutt B.I. Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996, 94:3087-3089.
34. Xu Y., Kumar D., Dyck J.R., Ford W.R., Clanachan A.S., Lopaschuk G.D., et al. AT1 and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol Heart Circ Physiol 2002, 282:H1206-1215.
35. Preckel B., Schlack W., Gonzalez M., Obal D., Barthel H., Thamer V. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in dog heart. Basic Res Cardiol 2000, 95:404-412.
36. Liu Y., Tsuchida A., Cohen M.V., Downey J.M. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbits heart. J Mol Cell Cardiol 1995, 27:883-892.
37. Diaz R.J., Wilson G.J. Sellective blockade of AT1 angiotensin II receptors abolished ischemic preconditioning in isolated rabit hearts. J Mol Cell Cardiol 1997, 29:129-139.
38. Hartman J.C., Hullinger T.G., Wall T.M. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 1993, 234:229-236.
39. Sladek T., Sladkova J., Kolar F., Papousek F., Cicutti N., Korecky B., et al. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 1996, 31:568-576.
40. Richard V., Ghaled B., Berdeaux A., Giudicelli J.F. Comparison of the EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs. Br J Pharmacol 1993, 110:969-974.
41. Schwarz E.R., Montino H., Fleischhauer J., Klues H.G., vom-Dahl J., Hanrath P. Angiotensin receptor antagonist EXP3174 reduces infarctt size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther 1997, 11:687-695.
42. Ryckwaert F., Colson P., Guillon G., Foex P. Cumulative effects of AT1 and AT2 receptor blockade on ischaemia-reperfusion recovery in rat hearts. Pharm Res 2005, 51:497-502.
43. Ohinata K., Fujiwata Y., Shingo F., Masaru I., Masatsugu H., Yoshikawa M. Orally administered novokinin, an angiotensin AT2 receptor agonist, suppresses food intake via prostaglandin E2-dependent mechanism in mice. Peptides 2009, 6:1105-1108.
44. Bosnyak S., Welungoda I.K., Hallberg A., Alterman M., Widdop R.E., Jones E.S. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, compound 21, evokes vasodepressor effects inconscious spontaneously hypertensive rats. Br J Pharmacol 2010, 159:709-716.
45. Barber M.N., Sampey D.B., Widdop R.E. AT2 Receptor Stimulation Enhances Antihypertensive Effect of AT1 Receptor Antagonist in Hypertensive Rats. Hypertension 1999, 34:1112-1116.